semaglutide and joint pain Treatment for Knee Arthritis Ozempic and GLP-1 Drugs: Risk

The Phase 2 trial data published in 2023 (Jastreboff et al., NEJM) included cardiovascular safety monitoring as a secondary endpoint

His migration toward eating more protein mainly fish has also helped his cholesterol and blood pressure, he said

Eli Lilly, Novo Nordisk expand operations amid GLP-1 drug boom Biopharma bigwigs Eli Lilly and Novo Nordisk are upping capacity to meet the rising demands of GLP-1 drugs

J., & Tang-Christensen, M

Our plans are built on a foundation of safety, efficacy, and personalization, ensuring that any solution we recommendwhether it's a prescription medication or a supportive supplement regimenis the right one for you

Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) showing promising early weight-loss and metabolic data in Phase 2 trials, but it is not yet approved in the UK and carries notable side effects and safety uncertainties